Finally, in a non-cancer related study, Wang et al. studied lipopolysaccharide-induced sepsis, using rigosertib as a MEK1-ERK signaling inhibitor, concluding that it prevented the production of proinflammatory cytokines induced by LPS by disrupting the activation of the MEK1-ERK signaling axis [45]. The gene discussed is MAP2K1; the disease is cancer.